SCHEMBL6736307

SCHEMBL6736307

CCCCOc1cccc2c1-c1ccccc1C2=CCOc1ccc(CC(OCC)C(=O)O)cc1

nearest known ligand 0.75

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 17/20 0.75
PPARG P37231 16/20 0.75
PPARD Q03181 13/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6736302 1.00 PPARA (0.75) PPARAPPARGPPARD
SCHEMBL6736011 0.96 PPARA (0.75) PPARAPPARGPPARD
SCHEMBL6736013 0.96 PPARA (0.75) PPARAPPARGPPARD
SCHEMBL6735399 0.92 PPARG (0.62) PPARAPPARGPPARD
SCHEMBL6735397 0.92 PPARG (0.62) PPARAPPARGPPARD
SCHEMBL6731720 0.92 PPARG (0.79) PPARAPPARGPPARD
SCHEMBL6731723 0.92 PPARG (0.79) PPARAPPARGPPARD
SCHEMBL6731592 0.88 PPARG (0.74) PPARAPPARGPPARD
SCHEMBL6734721 0.88 PPARG (0.62) PPARAPPARGPPARD
SCHEMBL6731590 0.88 PPARG (0.74) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683111-B2 SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY NOVO NORDISK A/S (DK) 2004-01-27 US claimed
US-20020115654-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-08-22 US claimed
EP-1123267-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP claimed
WO-2000023415-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO claimed
US-6683111-B2 SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY NOVO NORDISK A/S (DK) 2004-01-27 US disclosed
US-20020115654-A1 New compounds, their preparation and use JEPPESEN LONE (DK) 2002-08-22 US disclosed
US-6353018-B1 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2002-03-05 US disclosed
EP-1123267-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP disclosed
WO-2000023415-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115654-A1 New compounds, their preparation and use PPARG, PPARD, PPARA PPARA 3/4885PPARG 1/4885PPARD 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.